Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
News
All NewsCompaniesIndexesCurrency / ForexCommoditiesCryptocurrenciesETFInterest RatesEconomyThemesSectors 

UK's C4X Discovery signs $400 million licensing deal with AstraZeneca

11/28/2022 | 03:14am EST
A company logo is seen at the AstraZeneca site in Macclesfield

LONDON (Reuters) - British drug discovery company C4X Discovery said AstraZeneca had signed a licence worth up $402 million to develop an oral therapy for the treatment of inflammatory and respiratory diseases using its NRF2 Activator programme.

C4XD said on Monday it would receive pre-clinical milestone payments worth up to $16 million ahead of the first clinical trial, including $2 million upfront.

In addition, C4XD said it would receive a furtherpotential $385.8 million in clinical development and commercial milestones and tiered mid-single digit royalties upon commercialisation of any treatment. 

(Reporting by Paul Sandle; editing by Sarah Young)


ę Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -1.12% 10590 Delayed Quote.-4.53%
C4X DISCOVERY HOLDINGS PLC 1.45% 17.5 Delayed Quote.-4.17%
Latest news "Economy"
05:51pBoeing CEO hints at higher jet output, optimistic on China
RE
05:50pDC Comics fandom celebrates return of 'Swamp Thing' to big screen
RE
05:50pSK Hynix reports Q4 loss as demand weakens
RE
05:47pFactbox-What ending the U.S. COVID health emergency means for your pocket
RE
05:45pValero JV approves sustainable aviation fuel project at Texas plant
RE
05:45pThe WSJ Dollar Index Falls 1.50% This Month to 95.10 -- Data Talk
DJ
05:45pEuro Gains 1.52% to $1.0866 -- Data Talk
DJ
05:45pSterling Gains 1.81% to $1.2317 -- Data Talk
DJ
05:45pU.S. retail coffee prices rose as much as 50% in Q4 -report
RE
05:45pDollar Lost 0.77% to 130.11 Yen -- Data Talk
DJ
Latest news "Economy"